This lecture emphasizes the urgent need for early detection and intervention in CKD, noting that even mild cases require prompt action, including consideration of SGLT2 inhibitors like empagliflozin, which have demonstrated the potential to significantly delay kidney replacement therapy by over 26 years.

Bipolar disorder (BD) is a chronic condition associated with relapse and elevated suicide risk, for which lithium remains a key maintenance therapy to reduce recurrence, readmission, and self-harm. However, concerns about its renal and thyroid effects persist. 

This lecture by Professor Christoph Wanner emphasizes the importance of early diagnosis and treatment of chronic kidney disease (CKD), particularly in patients with cardiovascular comorbidities, advocating for comprehensive screening methods and timely treatment to improve patient outcomes.

Type 2 diabetes mellitus (T2DM) is known to be associated with a 33% greater risk of hospitalization for heart failure (HF) and an increase in the risk of cardiovascular and overall death.1 Patients with coexisting T2DM and chronic kidney disease (CKD) are at further risk of HF and ischemic events t

Atrial fibrillation, a distinct form of cardiovascular disease (CVD), is common in chronic kidney disease (CKD) patients.¹ It increases the risk of CKD patients developing stroke.² Intervention with warfarin is prevalent in patients with atrial fibrillation,

Secondary hyperparathyroidism (SHPT) is a very common condition in patients with chronic kidney disease (CKD).^1,2 Cinacalcet, a calcimimetic that is commonly used to treat patients with SHPT, has been recommended by well-recognized guidelines but appears to have some shortfalls with non-adherence issues.^3,4